Tuesday, September 29, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science

View original at finance.yahoo.com
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through open science, a new public-…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Abcam serves 750,000 researchers in over 130 countries to help them reach results faster in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders

    80% confidence
  • LIGAND-AI aims to change drug discovery by combining advanced laboratory technologies with computational methods to create a seamless pipeline from experiment to prediction, generating billions of data points

    80% confidence
  • The project brings together scientists and companies from across disciplines within an open science ecosystem, with diverse scientific communities coalescing around a common vision to generate and share valuable chemical data openly with the world

    80% confidence
  • LIGAND-AI represents the next frontier in drug discovery, combining cutting-edge AI with large-scale experimental science to build predictive models that will unlock thousands of new targets

    80% confidence
  • The project represents a major step toward the mission of Target 2035 to discover chemical modulators for every human protein by the year 2035

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,314 source documents archived
Query this data → isubstrate.com